Analysis of Pharmaceutical Care of One Patient with Diffuse Large B Cell Lymphoma Combine Tachycardia-bradycardia Syndrome Undergoing R-CHOP Chemotherapy

OBJECTIVE To explore the comprehensive treatment method of patients with tachycardia-bradycardia syndrome before using R-CHOP regimen chemotherapy and the precautions of pharmaceutical monitoring to ensure the safety and effeciency of chemotherapy. METHODS The clinical pharmacist participated in the R-CHOP regimen chemotherapy of a patient with tachycardia-bradycardia syndrome, analyzed from the aspects of treatment before chemotherapy and preventive measures for adverse reactions, and provided pharmaceutical care. RESULTS Patients with arrhythmia, such as tachycardia- bradycardia syndrome, must correct the heart rhythm while undergoing R-CHOP chemotherapy, and perform chemotherapy under strict supervision, and choose the drugs with less cardiac toxicity among the same drugs as possible, and closely monitor adverse reactions. CONCLUSION The clinical pharmacist conducts pharmacological monitoring of the patient's chemotherapy process, and comprehensively analyzes and summarizes the experience. It provides medication guidance for patients with lymphoma who have clinical cardiac insufficiency and must undergo R-CHOP chemotherapy.